SEATTLE, WA – (February 26, 2026) CounterX Therapeutics, Inc., a biotechnology company focused on developing novel antibody therapeutics and vaccines to address opioid overdose and dependence, today announced the formation of its Scientific Advisory Board (SAB). The SAB is comprised of nationally recognized leaders in addiction science, clinical medicine, and emergency care and will provide strategic guidance as the company advances its lead programs through clinical development.

The formation of the SAB represents an important step in strengthening CounterX’s translational and clinical strategy, supporting execution across preclinical validation, clinical trial design, regulatory engagement, and real-world implementation.

The inaugural Scientific Advisory Board includes:

Sandra Comer, Ph.D.
Professor of Neurobiology (in Psychiatry), Columbia University
Dr. Comer is a globally recognized authority in human behavioral pharmacology and substance use disorders. Her work has been foundational in characterizing the effects of opioids, including fentanyl, and in evaluating novel pharmacologic interventions using human laboratory and clinical models. Dr. Comer brings deep expertise in translational science, dose-response evaluation, and regulatory-relevant clinical study design, supporting efficient progression from preclinical data to clinical proof-of-concept.

Thomas Fitzpatrick, MD, MPH
Infectious Diseases Physician, University of Washington
Dr. Fitzpatrick is a infectious diseases physician and researcher with significant experience managing opioid use disorder and comorbid diseases. His work focuses on overdose and infection prevention among people who use drugs, including integrating and evaluating new interventions into public health systems. Dr. Fitzpatrick provides critical insight into clinical integration, community engagement, and population-level impact—key considerations for scalable clinical adoption.

Michael Genovese, MD, JD
Chief Medical Officer, Ascendant Detox Drug & Alcohol Rehab
Dr. Genovese is a board-certified physician with extensive frontline experience in addiction medicine and detoxification treatment, complemented by a legal background in healthcare regulation and compliance. As Chief Medical Advisor at Ascendant, he oversees real-world clinical programs treating patients with severe substance use disorders. His perspective informs patient selection, care pathways, and adoption dynamics critical to commercial success.

Marco Pravetoni, Ph.D., Founder and Chief Scientific Officer of CounterX Therapeutics, added, “The SAB’s collective experience across opioid pharmacology, addiction treatment, and emergency medicine enhances our ability to design clinically meaningful studies and de-risk drug development. Their guidance will be instrumental as we translate our antibody platform into differentiated therapeutic solutions.”

The Scientific Advisory Board will advise CounterX Therapeutics on scientific strategy, clinical development, pathways to regulatory approval and market adoption as the company advances its portfolio of monoclonal antibody therapeutics targeting fentanyl and other high-potency synthetic opioids.

About CounterX Therapeutics
CounterX Therapeutics is at the forefront of the battle against the opioid epidemic, exploiting cutting-edge biotechnology to develop life-saving therapeutics and vaccines. We combine scientific expertise with an experienced leadership team and a deep commitment to social impact. Our groundbreaking antibody therapies are designed to blunt the effects of opioids, reduce the risk of overdose and provide a path to recovery. Additionally, our pioneering vaccine technology aims to prevent addiction relapse by blocking the euphoric effects of opioids, empowering individuals to maintain a long-term recovery. Dr. Marco Pravetoni is the Founder and Chief Scientific Officer at CounterX Therapeutics and Professor of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine.

CTRX-101:
CTRX-101, is a monoclonal antibody against fentanyl that is in development for the prevention of accidental overdose in high-risk patients.  It is a long-acting subcutaneous injectable product that is not an opioid or controlled substance.  CTRX-101 was well-tolerated in preclinical models with no serious adverse events when used in combination with other medications for opioid use disorder (OUD).  It is not expected to cause opioid withdrawal and may be safe when used in combination with other medications.

FOR FURTHER INFORMATION, PLEASE CONTACT:

CounterX Therapeutics

Jacques Bouchy
Chief Business Officer
206.486.4755
ir@counterxtherapeutics.com